900 Davis Drive
P.O. Box 14505
Research Triangle Park
About Eisai Inc.Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. Eisai’s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.
Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company’s areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com.
242 articles with Eisai Inc.
BioArctic Receives MEUR 15 Milestone Payment from Eisai for Start of BAN2401 Confirmatory Phase 3 Study in Early Alzheimer's Disease
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company will receive a milestone payment of MEUR 15 from its partner Eisai for the achievement of the first patient being dosed in the global, single confirmatory Phase 3 study (Clarity AD) with BAN2401 in early Alzheimer´s disease.
Eisai Announces Data Presentations on Oncology Pipeline, including LENVIMA® (lenvatinib) plus KEYTRUDA® (pembrolizumab) Investigational Combination Therapy at ASCO 2019
Eisai today announced the presentation of new data and analyses in one oral presentation, 11 posters at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4 in Chicago.
5/10/2019Pharma and biotech companies strengthen their leadership teams with new hires at Immunocore, Eisai, Kyn, Bicycle, and more.
Dr. Harald Hampel hired as Vice President, Global Medical Affairs, Alzheimer's Disease; Dr. Michael Irizarry named Vice President, Clinical Research, Alzheimer's Disease
Eisai To Present Research Findings in Epilepsy and Sleep-Wake Disorders at the 2019 American Academy of Neurology Annual Meeting
Oral presentation highlighting assessment of next-morning residual effects of lemborexant, an investigational agent
The lynchpin to biotech and pharmaceutical drug development in the United States is arguably the greater Boston area, which includes the white hot square mile of talent and intellectual collaboration found in Kendall Square.
Company acquires international rights to Salagen® tablets (pilocarpine hydrochloride) (excluding Japan rights) and Panretin® (alitretinoin) gel 0.1% from Eisai Inc. for $30 million in cash plus approximately $3.3 million for purchased inventory and related prepayments. ADVANZ PHARMA will pay for the acquisition with cash on hand.
Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.
The debacle raised three broad questions: What will Biogen do next? Is the amyloid theory of Alzheimer’s now dead? And what else is going on in the Alzheimer’s drug development arena?
Cerveau Technologies, Inc. today announced a research collaboration agreement with Eisai Inc., which will enable Eisai to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain.
Perhaps the last big hope for a successful Alzheimer’s drug just died. Biogen and its collaboration partner, Eisai, announced they were discontinuing the global Phase III clinical trials of aducanumab in patients with mild cognitive impairment from Alzheimer’s.
Construction underway on state-of-the-art lab facility in new Alewife Research Center
BioArctic: Eisai Announces Timelines for the Single Confirmatory Phase 3 Study With BAN2401 in Warly Alzheimer's Disease
BioArctic AB informs that Eisai today announced the timelines for the single confirmatory Phase 3 study with BAN2401 in early Alzheimer´s disease patients i.e. mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease.
Real World Evidence on Use of Halaven® (eribulin mesylate) Injection Following CDK 4/6 Inhibitor to be Presented at 36th Annual Miami Breast Cancer Conference
The conference will be held from March 7-10 in Miami.
FDA Accepts Eisai's Supplemental New Drug Application (sNDA) to Update the Labeling for Anti-Obesity Agent BELVIQ® (lorcaserin HCl)
Proposed updated label includes data from CAMELLIA-TIMI 61, the first completed and largest cardiovascular outcomes trial for a weight loss agent
Eisai and Empatica Enter an Agreement to Co-Promote the Embrace2 Device for People Living With Epilepsy in the U.S.
Embrace2 is the first wrist-worn wearable in the field of epilepsy to be cleared as a medical device for detecting patterns that may be associated with convulsive seizures in children & adults
2/13/2019The battle of the bulge is ongoing and it appears that Americans are losing, according to a report from the U.S. Centers for Disease Control and Prevention. The report shows that Americans are losing height and gaining girth.
METAvivor and Presenting Sponsor Eisai Inc. Join Forces with AnaOno Intimates to Bring to Life the #ThisIsMBC Elements Campaign through Fashion
The fashion show, created to raise funds for metastatic breast cancer (MBC) research, featured MBC patient models, some of whom were featured in the Elements campaign.
BioArctic Announces That Eisai Will Initiate Phase 3 Confirmatory Study With BAN2401 in Early Alzheimer's Disease
BioArctic AB announced that Eisai stated at their Q3 FY2018 Financial Results Meeting on February 4, 2019 that a single Phase 3 confirmatory study of BAN2401 in early Alzheimer´s disease patients is under preparation and planned to be initiated within Eisai's FY2018 i.e. the first quarter 2019.
2/4/2019Eisai Co. and Purdue Pharma presented data at the Sleep Research Society’s Conference regarding their lemborexant for the treatment of insomnia. The meeting was held in Clearwater Beach, Florida.